{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34365113",
  "DateCompleted": {
    "Year": "2021",
    "Month": "10",
    "Day": "18"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "07",
        "Day": "24"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.coviro.2021.07.004",
      "S1879-6257(21)00075-4"
    ],
    "Journal": {
      "ISSN": "1879-6265",
      "JournalIssue": {
        "Volume": "50",
        "PubDate": {
          "Year": "2021",
          "Month": "Oct"
        }
      },
      "Title": "Current opinion in virology",
      "ISOAbbreviation": "Curr Opin Virol"
    },
    "ArticleTitle": "Proteases and variants: context matters for SARS-CoV-2 entry assays.",
    "Pagination": {
      "StartPage": "49",
      "EndPage": "58",
      "MedlinePgn": "49-58"
    },
    "Abstract": {
      "AbstractText": [
        "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), like other coronaviruses, relies on a flexible array of entry mechanisms, driven by the spike (S) protein. Entry is dependent on proteolytic priming, activation, and receptor binding; all of which can be variable, dependent on context. Here we review the implications of the complexity of SARS-CoV-2 entry pathways on entry assays that then drive our understanding of humoral immunity, therapeutic efficacy, and tissue restriction. We focus especially on the proteolytic activation of SARS-CoV-2 spike and how this constellation of proteases lends deeper insight to our understanding of arising variants and their putative role transmission or variable pathogenicity in vivo. In this review, we argue for better universal standards to assay virus entry as well as suggest best practices for reporting viral passage number, the cell line used, and proteases present, among other important considerations."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021 Elsevier B.V. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, United States."
          }
        ],
        "LastName": "Stevens",
        "ForeName": "Christian S",
        "Initials": "CS"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, United States."
          }
        ],
        "LastName": "Oguntuyo",
        "ForeName": "Kasopefoluwa Y",
        "Initials": "KY"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, United States. Electronic address: benhur.lee@mssm.edu."
          }
        ],
        "LastName": "Lee",
        "ForeName": "Benhur",
        "Initials": "B"
      }
    ],
    "GrantList": [
      {
        "GrantID": "T32 AI007647",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 AI123449",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 AI138921",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 AI071002",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 AI125536",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R21 AI115226",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "F31 AI154739",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "Curr Opin Virol",
    "NlmUniqueID": "101560941",
    "ISSNLinking": "1879-6257"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Spike Glycoprotein, Coronavirus"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "spike protein, SARS-CoV-2"
    },
    {
      "RegistryNumber": "EC 3.4.-",
      "NameOfSubstance": "Peptide Hydrolases"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "etiology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Peptide Hydrolases"
    },
    {
      "QualifierName": [
        "genetics",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Spike Glycoprotein, Coronavirus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Virus Internalization"
    }
  ]
}